论文部分内容阅读
目的分析紫杉醇序贯化疗治疗乳腺癌患者的疗效及毒副反应。方法 80例乳腺癌患者,依据随机数字表法将患者分为观察组和对照组,各40例。对照组患者采用4个周期的CEF100化疗方案,观察组患者在对照组基础上接受4个周期的序贯多西紫杉醇化疗。对比两组患者的疾病缓解情况,观察毒副反应发生情况。结果观察组完全缓解(CR)25例(62.5%),部分缓解(PR)11例(27.5%),稳定(SD)3例(7.5%),进展(PD)1例(2.5),总有效率(OR)为90.0%;对照组CR9例(22.5%),PR17例(42.5%),SD14例(35.0%),PD0例,OR为65.0%;观察组OR高于对照组,差异有统计学意义(P<0.05)。观察组6例患者在序贯多西紫杉醇化疗期间出现Ⅲ级及以上中性粒细胞减少症,采用G-CSF对症治疗后缓解;7例患者出现Ⅱ级血小板、白细胞减少反应。非造血系统毒性反应分别为脱发、恶心呕吐、肌肉关节疼痛、口腔黏膜、乏力,未出现心脏毒性和神经系统毒性反应。结论多西紫杉醇序贯化疗可提高治疗乳腺癌的疗效,且安全性性高。紫杉醇序贯化疗期间应重点做好血液学毒性预防工作,减少毒副反应。
Objective To analyze the efficacy and side effects of sequential chemotherapy with paclitaxel in patients with breast cancer. Methods Eighty patients with breast cancer were divided into observation group and control group according to random number table method, 40 cases in each. Patients in the control group received 4 cycles of CEF100 chemotherapy and patients in the observation group received sequential 4 cycles of docetaxel chemotherapy on a control-arm basis. Compare the two groups of patients with disease remission, observe the occurrence of toxic reactions. Results In the observation group, 25 patients (62.5%) had complete remission (CR), 11 patients (27.5%) had partial response (PR), 3 patients (7.5%) had stable response The OR of the control group was 90.0%. The control group had 9 cases (22.5%) of CR, 17 cases of PR (42.5%), 14 cases of SD (35.0%) and 0 cases of PD (65.0%). The OR of the observation group was higher than that of the control group Significance (P <0.05). Six patients in the observation group showed Grade Ⅲ and above neutropenia during sequential chemotherapy with docetaxel, and were relieved after symptomatic treatment with G-CSF. Grade Ⅱ thrombocytopenia and thrombocytopenia occurred in seven patients. Non-hematopoietic system toxicity were hair loss, nausea and vomiting, muscle and joint pain, oral mucosa, fatigue, no cardiotoxicity and nervous system toxicity. Conclusion Docetaxel sequential chemotherapy can improve the efficacy of breast cancer treatment, and high safety. During the sequential chemotherapy of paclitaxel, hematological toxicity prevention should be focused on reducing the side effects.